Plain-English translation of NCT06581328 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing vedolizumab, a medication that helps calm the inflammation in your gut, for people with moderate to severe ulcerative colitis or Crohn's disease. You would receive the medication for about one year: first as intravenous infusions (into your vein) for the first 6 weeks, then as injections under your skin every 2 weeks for the rest of the study. The main goal is to see how many people go into remission—meaning their symptoms disappear or improve significantly—after 3.5 months of treatment.
Ulcerative colitis and Crohn's disease cause painful inflammation, bleeding, and diarrhea that can seriously affect quality of life. While this medication already exists, this trial is studying whether the newer injectable form works well in everyday community clinics, where many patients are actually treated, rather than only in specialized research hospitals.
You likely qualify if…
You likely don't qualify if…
You would visit a community clinic multiple times over approximately one year. During the first 6 weeks, you would receive two intravenous infusions of the medication into your arm. After that, you would switch to self-injections under your skin every 2 weeks, which you may be able to do at home. Researchers will check whether your symptoms have disappeared or improved after 3.5 months; if the medication isn't working for you by that point, you can stop and try a different treatment. Everyone will have follow-up visits at 6 months and 1 year, and a final check 4.5 months after your last dose.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States